1. Academic Validation
  2. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

  • MAbs. 2018 May/Jun;10(4):678-691. doi: 10.1080/19420862.2018.1452580.
Neungseon Seo 1 Alla Polozova 2 Mingxuan Zhang 2 Zachary Yates 2 Shawn Cao 3 Huimin Li 3 Scott Kuhns 3 Gwendolyn Maher 3 Helen J McBride 1 Jennifer Liu 1
Affiliations

Affiliations

  • 1 a Biosimilars, Amgen Inc., One Amgen Center Drive , Thousand Oaks , CA , USA.
  • 2 b Process Development, Amgen Inc. , Cambridge , MA , USA.
  • 3 c Process Development, Amgen Inc., One Amgen Center Drive , Thousand Oaks , CA , USA.
Abstract

ABP 215 is a biosimilar product to bevacizumab. Bevacizumab acts by binding to vascular endothelial growth factor A, inhibiting endothelial cell proliferation and new blood vessel formation, thereby leading to tumor vasculature normalization. The ABP 215 analytical similarity assessment was designed to assess the structural and functional similarity of ABP 215 and bevacizumab sourced from both the United States (US) and the European Union (EU). Similarity assessment was also made between the US- and EU-sourced bevacizumab to assess the similarity between the two products. The physicochemical properties and structural similarity of ABP 215 and bevacizumab were characterized using sensitive state-of-the-art analytical techniques capable of detecting small differences in product attributes. ABP 215 has the same amino acid sequence and exhibits similar post-translational modification profiles compared to bevacizumab. The functional similarity assessment employed orthogonal assays designed to interrogate all expected biological activities, including those known to affect the mechanisms of action for ABP 215 and bevacizumab. More than 20 batches of bevacizumab (US) and bevacizumab (EU), and 13 batches of ABP 215 representing unique drug substance lots were assessed for similarity. The large dataset allows meaningful comparisons and garners confidence in the overall conclusion for the analytical similarity assessment of ABP 215 to both US- and EU-sourced bevacizumab. The structural and purity attributes, and biological properties of ABP 215 are demonstrated to be highly similar to those of bevacizumab.

Keywords

ABP 215; analytical similarity assessment; bevacizumab; biosimilar; function; structure.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99476
    Anti-VEGFA Antibody